Targeted Oncologics ISO Companion Diagnostics To Find Attractive Patients
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The molecularly targeted oncologics that have energized oncology drug development and treatment over the last decade have sparked a secondary boom in companion diagnostics. After all, a drug for a tumor expressing a particular receptor profile is not particularly useful unless physicians can identify patients with that profile.